16 studies found for:    AKT1
Show Display Options
Rank Status Study
1 Recruiting Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Conditions: Advanced Solid Malignancy;   Safety and Tolerability;   Pharmacokinetics;   Pharmacodynamics;   Tumour Response;   Advanced or Metastatic Breast Cancer;   Ovarian Cancer;   Cervical Cancer;   Endometrial Cancer;   PIK3CA;   AKT1;   ER+;   HER2+
Intervention: Drug: AZD5363
2 Recruiting Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
Condition: Neoplasms
Intervention: Drug: BAY1125976
3 Completed
Has Results
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Bevacizumab and Erlotinib
4 Enrolling by invitation A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations
Condition: Schizophrenia
Intervention:
5 Completed A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001 AM5)(COMPLETED)
Condition: Advanced Cancer
Interventions: Drug: Comparator: MK-8033;   Drug: Comparator: MK-8033 +/- omeprazole
6 Recruiting Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations
Condition: Cardiovascular Abnormalities
Intervention: Drug: Sirolimus
7 Recruiting Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: laboratory biomarker analysis
8 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma
Interventions: Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: laboratory biomarker analysis
9 Active, not recruiting A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Conditions: Ovarian Sarcoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis
10 Recruiting Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: Akt inhibitor MK2206;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis
11 Active, not recruiting A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
Conditions: Acute Lymphoblastic Leukemia;   Leukemia, Myelocytic, Acute;   Chronic Myelogenous Leukemia With Crisis of Blast Cells
Intervention: Drug: BEZ235
12 Recruiting A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Intervention: Drug: RAD001
13 Active, not recruiting Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: sorafenib tosylate;   Biological: bevacizumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
14 Unknown  The Roles of Neutrophil Elastase in Lung Cancer
Conditions: Lung Cancer;   Chronic Obstructive Pulmonary Diseases
Intervention:
15 Completed
Has Results
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes
Conditions: Cowden's Disease;   Hamartoma Syndrome, Multiple
Interventions: Radiation: fludeoxyglucose F 18;   Drug: sirolimus;   Other: Clinical Videography
16 Recruiting Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment
Condition: Malignant Solid Neoplasms
Interventions: Drug: Nilotinib (400 mg BID);   Drug: Everolimus (10 mg QD);   Drug: Sorafenib (400 mg BID);   Drug: Lapatinib (1500 mg QD);   Drug: Pazopanib (800 mg QD)

Indicates status has not been verified in more than two years